Australia's most trusted
source of pharma news
Friday, 29 March 2024
Posted 11 August 2022 AM
The decision by the Federal Government to push forward with the rollout of Bavarian Nordic's vaccine for monkeypox, without TGA approval, has put the spotlight on emergency use powers.
The TGA cannot compel a sponsor to apply for registration in the ARTG and the Danish manufacturer has so far not sought registration for its smallpox vaccine Jynneos.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.